Co-stimulatory molecules as targets for treatment of lupus

Clinical Immunology

Volumn 148, Issue 3, 2013, Pages 369-375

  Merrill, Joan T ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Abatacept; CD40; CD40 ligand; Co stimulatory molecules; CTLA4; CTLA4Ig

Indexed keywords

A 20; ABATACEPT; AMG 557; ANGIOTENSIN RECEPTOR ANTAGONIST; B7 ANTIGEN; BG 9588; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOUBLE STRANDED DNA ANTIBODY; HUMAN MONOCLONAL ANTIBODY; INDUCIBLE T CELL COSTIMULATOR LIGAND; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; PREDNISONE; RECOMBINANT GAMMA INTERFERON; TORALIZUMAB; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW CELL; COMPLEMENT ACTIVATION; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DISEASE EXACERBATION; DOSE DENSIFICATION; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; INTERVENTION STUDY; LIGAND BINDING; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THROMBOSIS; UNSPECIFIED SIDE EFFECT; URINE SEDIMENT;

ABATACEPT; CD40; CD40 LIGAND; CO-STIMULATORY MOLECULES; CTLA4; CTLA4IG;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; CD40 LIGAND; CLINICAL TRIALS AS TOPIC; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR LIGAND; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84881115498     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.04.012     Document Type: Review

References (35)

1. Hughes T., Adler A., Kelly J.A., Kaufman K.M., Williams A.H., Langefeld C.D., Brown E.E., Alarcn G.S., Kimberly R.P., Edberg J.C., Ramsey-Goldman R., Petri M., Boackle S.A., Stevens A.M., Reveille J.D., Sanchez E., Martín J., Niewold T.B., Vilá L.M., Scofield R.H., Gilkeson G.S., Gaffney P.M., Criswell L.A., Moser K.L., Merrill J.T., Jacob C.O., Tsao B.P., James J.A., Vyse T.J., Alarcón-Riquelme M.E., BIOLUPUS Network, Harley J.B., Richardson B.C., Sawalha A.H. Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum. 2012, 64:485-492.
2. Guo W., Smith D., Aviszus K., Detanico T., Heiser R.A., Wysocki L.J. Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. J. Exp. Med. 2010, 207:2225-2237.
3. Nambiar M.P., Enyedy E.J., Warke V.G., Krishnan S., Dennis G., Kammer G.M., Tsokos G.C. Polymorphisms/mutations of TCR-zeta-chain promoter and 3' untranslated region and selective expression of TCR zeta-chain with an alternatively spliced 3' untranslated region in patients with systemic lupus erythematosus. J. Autoimmun. 2001, 16:133-142.
4. Costenbader K.H., Gay S., Alarcon-Riquelme M.E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?. Autoimmun. Rev. 2012, 11:604-609.
5. Nagy G., Koncz A. Perl A T- and B-cell abnormalities in systemic lupus erythematosus. Crit. Rev. Immunol. 2005, 25:123-140.
6. Apostolidis S.A., Lieberman L.A., Kis-Toth K., Crispín J.C., Tsokos G.C. The dysregulation of cytokine networks in systemic lupus erythematosus. J. Interferon Cytokine Res. 2011, 31:769-779.
7. Craft J.E. Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. Rheumatol. 2012, 8:337-347.
8. Kalunian K.C., Davis J.C., Merrill J.T., Totoritis M.C. Wofsy D treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46:3251-3258.
9. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003, 48:719-727.
10. Merrill J.T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D.J., Bae S.C., Sigal L., Becker J.C., Kelly S., Raghupathi K., Li T., Peng Y., Kinaszczuk M., Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62:3077-3087.
11. Furie R., Nicholls K., Cheng T., Houssiau F., Burgos-Vargas R., Chen S.L., Aranda R., Meadows-Shropshire S., Meadows-Shropshire S., Kinaszczuk M., Kinaszczuk M., Merrill J.T. Efficacy and Safety of Abatacept over 12 Months in Patients with Lupus Nephritis: Results From a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study 2011, American College of Rheumatology, (abstract 2469).
12. Alaaeddine Nada, Hassan Ghada S., Yacoub Daniel, Mourad Walid CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin. Dev. Immunol. 2012, 2012:490148.
13. Bugert P., Pabinger I., Stamer K., Vormittag R., Skeate R.C., Wahi M.M., Panzer S. The risk for thromboembolic disease in lupus anticoagulant patients due to pathways involving P-selectin and CD154. Thromb. Haemost. Apr 2007, 97(4):573-580.
14. Robles-Carrillo L., Meyer T., Hatfield M., Desai H., Dávila M., Langer F., Amaya M., Garber E., Francis J.L., Hsu Y.M., Amirkhosravi A. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. Aug 1 2010, 185(3):1577-1583.
15. Sidiropoulos P.I., Boumpas D.T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004, 13(5):391-397.
16. Kyttaris V.C., Zhang Z., Kampagianni O., Tsokos G.C. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 2011, 63:2058-2066.
17. Hovelmeyer N., Reissig S., Thi Xuan N., et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur. J. Immunol. 2011, 41:595-601.
18. Tavares R.M., Turer E.E., Liu C.L., et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010, 33:181-191.
19. Odegard J., DiPlacido L.D., Greenwals L., Kashgarian M., Kono H., Dong C., Flavell R.A., Craft J. ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus. J. Immunol. 2009, 182:4076-4084.
20. Harada Hiroshi, Salama Alan D., Sho Masayuki, Izawa Atsushi, Sandner Sigrid E., Ito Toshiro, Akiba Hisaya, Yagita Hideo, Sharpe Arlene H., Freeman Gordon J., Sayegh Mohamed H. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J. Clin. Invest. 2003, 112:234-243.
21. (NCT00774943). http://www.clinicaltrials.gov.
22. Ichinose K., Juang Y.T., Crispín J.C., Kis-Toth K., Tsokos G.C. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 2011, 63:523-529.
23. Weisman M.H., Durez P., Hallegua D., et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J. Rheumatol. 2006, 33:2162-2166.
24. Davis P.M., Abraham R., Xu L., Nadler S.G., Suchard S.J. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007, 34:2204-2210.
25. Linsley P.S., Nadler S.G. The clinical utility of inhibiting CD28-mediated costimulation. Immunol. Rev. 2009, 229:307-321.
26. Daikh D.I., Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 2001, 166:2913-2916.
27. Daikh D.I., Finck B.K., Linsley P.S., Hollenbaugh D., Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. 1997, 159:3104-3108.
28. Spindler A.J., Guzman R., Bijl M., Jayne D., Furie R.A., Maciuca R., Shahdad S., Close D., Brunetta P., Drappa J. Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III BELONG study. Arthritis Rheum. 2010, 62:S606. (abstract), (Suppl.).
29. Furie R., Nicholls K., Cheng T.T., Houssiau F., Burgos-Vargas R., Chen S.L., Hillson J., Kinaszczuk M., Merrill J.T. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis Rheum. 2011, 63(10):2469. (Suppl.).
30. ACCESS study: clinicaltrials.gov/show/NCT00774852.
31. Wofsy D., Hillson J.L., Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012, 64:3660-3665.
32. Furie R.A., Petri M.A., Wallace D.J., Ginzler E.M., Merrill J.T., Stohl W., Chatham W.W., Strand V., Weinstein A., Chevrier M.R., Zhong Z.J., Freimuth W.W. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. Sep 15 2009, 61(9):1143-1151.
33. Merrill J., Buyon J., Furie R., Latinis K., Gordon C., Hsieh H.J., Brunetta P. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus Jun 2011, 20(7):709-716. (Epub 2011 Apr 8).
34. Ruperto N., Hanrahan L.M., Alarcón G.S., Belmont H.M., Brey R.L., Brunetta P., Buyon J.P., Costner M.I., Costner M.I., Cronin M.E., Dooley M.A., Filocamo G., Fiorentino D., Fortin P.R., Franks A.G., Gilkeson G., Ginzler E., Gordon C., Grossman J., Hahn B., Isenberg D.A., Kalunian K.C., Petri M., Sammaritano L., Sánchez-Guerrero J., Sontheimer R.D., Strand V., Urowitz M., von Feldt J.M., Werth V.P., Merrill J.T., Lupus Foundation of America Inc., International Flare Consensus Initiative International consensus for a definition of disease flare in lupus. Lupus 2011, 20:453-462.
35. Merrill J.T., Erkan D., Buyon J.P. Challenges in bringing the bench to bedside in drug development for SLE. Nat. Rev. Drug Discov. 2004, 3:1036-1046. (Review).